Intellia Therapeutics, Inc.

NASDAQ:NTLA

Biotechnology

Healthcare
$9.52 +0.14%

+$0.02 today

Market cap
$1.34B
Beta
1.81
P/E (TTM)
-4.6
EPS (TTM)
-$3.33
52W Low $7.95High $28.25

Volume 9.96M

Average 6.11M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$348.88M

FY 2025 · Annual

Investing Cash Flow

$125.57M

FY 2025 · Annual

+0.0% YoY

Financing Cash Flow

$185.75M

FY 2025 · Annual

+0.0% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(267.89M)(474.19M)(481.19M)(519.02M)(519.02M)
Depreciation & Amortization6.89M7.57M8.98M10.29M10.29M
Deferred Income Tax8.93M0000
Stock-Based Compensation47.01M91.4M134.05M154.27M154.27M
Change in Working Capital(22.9M)(53.87M)(52.45M)11.88M(73.75M)
Accounts Receivables99K(1.74M)(32.69M)27.94M(951K)
Inventory7.82M0000
Accounts Payables529K(4.58M)2.52M6.8M5.99M
Other Working Capital(31.36M)(47.55M)(22.29M)(22.86M)(78.79M)
Other Non-Cash Items2.94M95.8M(3.47M)(6.3M)79.34M
Operating Cash Flow(225.03M)(333.29M)(394.09M)(348.88M)(348.88M)
Capital Expenditures(12.76M)(58.39M)(13.99M)(5.78M)(5.78M)
Acquisitions (Net)(3M)(44.68M)000
Purchases of Investments(1.02B)(429.03M)(904.46M)(935.57M)(935.57M)
Sales of Investments485.6M647.58M887.1M1.07B1.05B
Other Investing Activities044.83M0020.97M
Investing Cash Flow(550.78M)160.31M(31.35M)125.57M125.57M
Debt Repayment00000
Common Stock Issued693.57M565.79M119.8M176.9M131.49M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities43.12M17.17M10.53M8.85M54.26M
Financing Cash Flow736.69M582.96M130.32M185.75M185.75M
Effect of Forex Changes00000
Net Change in Cash(39.12M)409.98M(295.11M)(37.57M)(37.57M)
Free Cash Flow(237.79M)(391.68M)(408.07M)(354.66M)(354.66M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$519.0M
+ D&A$10.3M
+ Stock-Based Comp$154.3M
+ Deferred Tax$0
- Working Capital-$73.8M
+ Other Non-Cash$79.3M
= Operating Cash Flow-$348.9M
- Capex-$5.8M
= Free Cash Flow-$354.7M

Analysis

FY2025 free cash flow is -$354.7M. FCF conversion is 68.3% of net income. Operating cash flow was -$348.9M, with capex of -$5.8M. The largest bridge item is Stock-Based Comp at $154.3M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-K/A8-K/A filingNov 13, 2026
8-KCurrent reportNov 12, 2026
SC 13GSC 13G filingNov 10, 2026
10-QQuarterly reportNov 5, 2026
8-KCurrent reportNov 5, 2026

Does NTLA generate free cash flow?

Intellia Therapeutics, Inc. (NTLA) generated -$354.66M of free cash flow in fiscal 2025.

How much operating cash flow does NTLA produce?

Operating cash flow was -$348.88M, before capital expenditures of $5.78M.